Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05902169

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Led by CarThera · Updated on 2026-04-24

560

Participants Needed

48

Research Sites

230 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated. The SonoCloud-9 (SC9) is an investigational device using ultrasound technology and specially developed to open the BBB in the area of and surrounding the tumour. The transient opening of the BBB allows more drugs to reach the brain tumour tissue. Carboplatin is a chemotherapy that is approved to treat different cancer types alone or in combination with other drugs, and has been used in the treatment of glioblastoma. Despite its proven efficacy in the laboratory on glioblastoma cells, carboplatin does not readily cross the BBB in humans. A clinical trial has shown that in combination with the SonoCloud-9, more carboplatin can reach the brain tumour tissue. The objective of the proposed trial is to show that the association - carboplatin with the SonoCloud-9 - will increase efficacy of the drug in patients with recurrent glioblastoma.

CONDITIONS

Official Title

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed glioblastoma without IDH mutation
  • Prior surgery or biopsy and standard or hypofractionated radiotherapy completed
  • At least one line of maintenance chemotherapy or immune/biological therapy received
  • First unequivocal disease progression with measurable tumor documented by MRI within 14 days
  • Minimum 12 weeks since last radiotherapy, unless new lesion or confirmed viable tumor
  • Candidate for craniotomy and at least 50% resection of enhancing tumor
  • Maximum tumor diameter prior to inclusion is 5 cm or less
  • WHO performance status 2 or better (Karnofsky 70 or higher)
  • Age 18 years or older
  • Recovered from acute toxic effects of prior anticancer therapies according to specified intervals
  • Adequate blood counts, liver and kidney function within 14 days
  • Able to understand trial and provide informed consent
  • Negative pregnancy test if of childbearing potential and agree to birth control
  • Male patients agree to condom use and refrain from sperm donation during and after treatment
  • Covered by a health plan and social security scheme as required
Not Eligible

You will not qualify if you...

  • Multifocal enhancing tumor outside a 5 cm diameter area
  • Tumor located in the posterior fossa
  • Known BRAF or NTKR mutations
  • Risk factors for surgical site infection or recent multiple neurosurgeries
  • Use of high or stable dose corticosteroids above specified levels prior to inclusion
  • Contraindication to carboplatin, lomustine, or temozolomide
  • Known allergies to ultrasound resonator components
  • Previous bevacizumab treatment for reasons other than edema
  • Peripheral neuropathy grade 2 or higher
  • Uncontrolled epilepsy or intracranial pressure
  • Known intracranial aneurysm or significant hemorrhage
  • Presence of unremovable implants such as coils, clips, or stents
  • Need for continuous antiplatelet or anticoagulation therapy without possible interruption
  • Use of enzyme-inducing antiepileptic drugs unless switched to other regimens
  • Other malignancies within last 3 years except certain skin or cervical cancers
  • Active or chronic infections
  • Significant cardiac or pulmonary conditions
  • Known sensitivity to gadolinium or contrast agents
  • Impaired temperature regulation or sensation
  • Pregnancy or breastfeeding
  • Any serious medical or psychological condition affecting treatment or evaluation
  • Legal guardianship or deprivation of liberty
  • Major medical illnesses impairing ability to receive treatment or confounding evaluation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 48 locations

1

Mayo Clinic Arizona

Phoenix, Arizona, United States, 805054

Active, Not Recruiting

2

University of California, San Francisco

San Francisco, California, United States, 94143

Active, Not Recruiting

3

UCHealth

Aurora, Colorado, United States, 80011

Active, Not Recruiting

4

Mayo Clinic of Jacksonville Florida

Jacksonville, Florida, United States, 32224

Active, Not Recruiting

5

Miami Cancer Institute

Miami, Florida, United States, 33176

Active, Not Recruiting

6

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Active, Not Recruiting

7

Winship Cancer Institute at Emory University

Atlanta, Georgia, United States, 30322

Active, Not Recruiting

8

Northwestern University

Chicago, Illinois, United States, 60611

Active, Not Recruiting

9

Indiana University Health

Indianapolis, Indiana, United States, 46202

Active, Not Recruiting

10

John Hopkins University

Baltimore, Maryland, United States, 21287

Active, Not Recruiting

11

Mayo Clinic Rochester

Rochester, Minnesota, United States, 55905

Active, Not Recruiting

12

Weill Cornell Medicine

New York, New York, United States, 10021

Active, Not Recruiting

13

NewYork-Presbyterian / Columbia University Irving Medical Center

New York, New York, United States, 10032

Active, Not Recruiting

14

Lennox Hill Hospital

New York, New York, United States, 10075

Active, Not Recruiting

15

University of North Carolina

Chapel Hill, North Carolina, United States, 27516

Active, Not Recruiting

16

Penn State Health Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States, 17033

Active, Not Recruiting

17

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Active, Not Recruiting

18

University of Texas Houston Health Science Center

Houston, Texas, United States, 77030

Active, Not Recruiting

19

University of Utah, Hunstman Cancer Institute

Salt Lake City, Utah, United States, 84112

Active, Not Recruiting

20

Medizinische Universitaet Innsbruck

Innsbruck, Austria, 6020

Active, Not Recruiting

21

Universitair Ziekenhuis Brussel

Brussels, Belgium

Actively Recruiting

22

Universitair Ziekenhuis Leuven

Leuven, Belgium

Active, Not Recruiting

23

CHU de Liège

Liège, Belgium

Actively Recruiting

24

Rigshospitalet

Copenhagen, Denmark, 2100

Active, Not Recruiting

25

Odense University Hospital

Odense, Denmark, 5000

Active, Not Recruiting

26

Hôpital Neurologique Pierre Wertheimer

Bron, France

Active, Not Recruiting

27

Hôpital de La Timone

Marseille, France

Actively Recruiting

28

Hôpital de la Pitié-Salpêtrière

Paris, France

Actively Recruiting

29

Hôpital Foch

Suresnes, France, 92150

Active, Not Recruiting

30

Charité Universitätsmedizin Berlin

Berlin, Germany, 10117

Active, Not Recruiting

31

Klinikum Chemnitz gGmbH

Chemnitz, Germany, 09113

Active, Not Recruiting

32

Neurochirurgie uniklinik Köln

Cologne, Germany

Active, Not Recruiting

33

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, Germany, 01307

Active, Not Recruiting

34

Universitätsklinikum Essen Klinik für Neurologie

Essen, Germany, 45147

Active, Not Recruiting

35

Ospedale Bellaria

Bologna, Italy, 40139

Active, Not Recruiting

36

Ospedale Civile di Livorno

Livorno, Italy, 57124

Active, Not Recruiting

37

Istituto Oncologico Veneto

Padua, Italy

Active, Not Recruiting

38

Irccs Istituto Clinico Humanitas

Rozzano, Italy, 20089

Active, Not Recruiting

39

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

Torino, Italy, 10126

Active, Not Recruiting

40

Erasmus Medisch Centrum (Erasmus MC)

Rotterdam, Netherlands

Active, Not Recruiting

41

Haaglanden Medisch Centrum

The Hague, Netherlands, 2263

Active, Not Recruiting

42

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain, 08035

Active, Not Recruiting

43

Hospital Clinic de Barcelona

Barcelona, Spain, 08036

Active, Not Recruiting

44

Hospital Universitario HM Sanchinarro

Madrid, Spain, 28050

Active, Not Recruiting

45

Hospital Universitario 12 de Octubre

Madrid, Spain

Active, Not Recruiting

46

Hospital Universitario Virgen del Rocío

Seville, Spain, 41013

Active, Not Recruiting

47

Inselspital Bern

Bern, Switzerland, 3010

Active, Not Recruiting

48

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Switzerland, 1011

Active, Not Recruiting

Loading map...

Research Team

C

Carole Desseaux

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here